Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
Letter ·
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease.
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence Development (CED) for monoclonal antibody treatments for Alzheimer’s disease. In these comments, NAMD underscored that the proposed coverage determination may have significant financial impacts on state Medicaid programs, and that states must therefore retain the ability to set appropriate Medicaid utilization controls. NAMD also encouraged Congress to explore additional tools to help state Medicaid programs address future high-cost specialty drugs.
Related resources
NAMD Joins State Associations in Requesting that Congress and the Administration Help States Prepare for the End of the Public Health Emergency
On October 21, 2021, NAMD, ADvancing States, the National Association of State Directors of Developmental Disabilities Services, and...
NAMD Urges CMS to Mitigate State Costs on Controversial Alzheimer’s Drug
In formal comments, NAMD calls on Medicare to step up and cover the Alzheimer’s drug Aduhelm. Failure to...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.